Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 696-700

  James, Joseph K ^a,d   Palmer, Shirley M ^a,e   Levine, Donald P ^b   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS;

EID: 0030061099     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.696     Document Type: Article

References (37)

1. Ackerman, B. H., A. M. Vanniere, and E. B. Eudy. 1992 Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharnacodynamic response Antimicrob Agents Chemother 36:1766-1769.
2. Barois, A., B. Estournet, J. B. Moranne, J. Piliot, C. Chabenat, and J. Bataille. 1986. Staphylococcal infection of cerebral ventricles treated with vancomycin by continuous infusion. Presse Med. 15:1805-1808.
3. Barriere, S. L., E. Ely, J. E. Kapusnik, and J. G. Gambertoglio. 1985. Analysis of a new method for assessing activity of combinations of antimicrobials area under the bactericidal activity curve J. Antimicrob. Chemother 16:49-59
4. Brinquin, L., J. M. Rousseau, G. Boulesteix, Y. Diraison, and J. P. Bonsignour. 1993. Continuous infusion of vancomycin in post-neurosurgical staphylococcal meningitis in adults. Presse Med. 22:1815-1817.
5. Bulychev, A. (Wayne State University), 1995. Personal communication.
6. Bush, K. 1989. Classification of β-lactamases: groups I, 2a, 2b, and 2b Antimicrob. Agents Chemother. 33:264-270.
7. Cantu, T. G., N. A. Yamanaka-Yuen, and P. S. Lietman. 1994 Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. 18:533-543.
8. Cockroft, D. W., and M. H. Gault. 1976. Prediction of creatmine clearance from seruin creatinine. Nephron 16:31-41.
9. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
10. Edwards, D. J., and S. Pancorho. 1987. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin. Pharm. 6:652-654.
11. Farber, B. F., and R. C. Moellering. 1983. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob. Agents Chemother. 23:138-141.
12. Fox, J. L., and M. L. Lamson. 1987. RSTRIP user handbook. MicroMath, Inc., Salt Lake City, Utah.
13. Freeman, C. D., R. Quintiliani, and C. H. Nightingale. 1993. Vancomycin therapeutic drug monitoring: is it necessary? DICP Ann. Pharmacother. 27:594-598.
14. Gibaldi, M., and J. D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 414. Marcel Dekker, Inc., New York.
15. Louria, D. B., T. Kaminski, and J. Buchnian. 1961 Vancomycin in severe staphylococcal infections. Arch. Intern. Med. 107:225-240.
16. Mattie, H., W. A. Craig, and J. C. Pechere. 1989. Review: determinants of efficacy and toxicity of aminoglycosides. J. Antimicrob. Chemother. 24:281-293.
17. Moellering, R. C., Jr. 1994. Editorial: monitoring serum vancomycin levels: climbing the mountain because it is there? Clin. Infect. Dis. 18:544-546.
18. Moore, R. D., P. S. Lietman, and C. R. Smith. 1984. The association of aminoglycoside plasma levels with mortality in patients with gram-negative pneumonia. J. Infect. Dis. 149:443-448.
19. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-97.
20. National Committee for Clinical Laboratory Standards. 1992 Methodology for the serum bactericidal test Tentative guidelines. Document M21-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution and antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard. Document M7-A3. National Committee for Clinical Laboratory Standards. Villanova, Pa.
22. Noone, P., T. M. C. Parsons, J. R. Pattison, R. C. B. Slack, D. Garfield-Davies, and K. Hughes. 1974. Experience in monitoring gcntamicin therapy during treatment of serious gram-negative sepsis. Br. Med. J. i:477-481.
23. Oster, S. E., V. A. Chirurgi, A. A. Goldberg, S. Aiken, and R. E. McCabe. 1990, Ampicillin-resistant enterococcal species in an acute-care hospital Antimicrob. Agents Chemother. 34:1821-1823.
24. Polk, R. E., D. P. Healy, L. B. Schwartz, D. T. Rock, M. L. Garson, and K. Roller. 1988. Vancomycin and the red-man syndrome: pharmacodynamics of histaminc release. J. Infect Dis 157:502-507.
25. Pryka, R. D. 1994. Vancomycin serum concentration monitoring: a continued debate. DICP Ann. Pharmacother. 28:1397-1399.
26. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program version 2 1 for area and moments in pharmacokinetic analysis Comput. Programs Biomed. 16:203-216.
27. Rybak, M. J., L. M. Albrecht, J. R. Berman, L. H. Warbasse, and C. K. Svensson. 1990. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob. Agents Chemother. 34:792-795.
28. Rybak, M. J., E. M. Bailey, K. C. Lamp, and G. W. Kaatz. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
29. Schadd, U. B., G. H. McCracken, and J. D. Nelson. 1980. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J. pediatr. 96:119-126.
30. Sehentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25:1050-1057.
31. Smith, I. L., and J. J. Schentag. 1984. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J. Pharm. Sci. 73:281-282.
32. Sorrell, T. C., D. R. Packham, S. Shanker, M. Foldes, and R. Munro. 1982. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 97:344-350.
33. Stratton, C. W. 1987. The role of the microbiology laboratory in the treatment of infective endocarditis. J. Antimicrob. Chemother. 20(Suppl. A):41-49.
34. Thomas, F., P. Michel, and Y. Raveud. 1988. Treatment of staphylococcal infections in adults by continuous intravenous infusion of vancomycin as single drug therapy. Sem. Hop. Paris 65:215-218.
35. Watanakunakorn, C. 1981. The antibacterial action of vancomycin. Rev. Infect. Dis. 3:S210-S215.
36. Weinstein, M. P., C. W. Stratton, A. Ackley, H. B. Hawley, P. A. Robinson, B. D. Fisher, D. V. Alcid, D. S. Stephens, and L. B. Relier. 1985. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am. J Med, 78:262-269.
37. Zimmermann, A. E., B. G. Katona, and K. I. Plaisance. 1995. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 15:85-91.